ES2768651T3 - Composición farmacéutica sólida - Google Patents

Composición farmacéutica sólida Download PDF

Info

Publication number
ES2768651T3
ES2768651T3 ES14787908T ES14787908T ES2768651T3 ES 2768651 T3 ES2768651 T3 ES 2768651T3 ES 14787908 T ES14787908 T ES 14787908T ES 14787908 T ES14787908 T ES 14787908T ES 2768651 T3 ES2768651 T3 ES 2768651T3
Authority
ES
Spain
Prior art keywords
tio
mpos
ico
tic
ica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14787908T
Other languages
English (en)
Spanish (es)
Inventor
Hiroshi Uchida
Masataka Hanada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2768651T3 publication Critical patent/ES2768651T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/20—Mixing gases with liquids
    • B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
    • B01F23/235—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids for making foam

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES14787908T 2013-04-25 2014-04-24 Composición farmacéutica sólida Active ES2768651T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013092171 2013-04-25
PCT/JP2014/002308 WO2014174846A1 (ja) 2013-04-25 2014-04-24 固形医薬組成物

Publications (1)

Publication Number Publication Date
ES2768651T3 true ES2768651T3 (es) 2020-06-23

Family

ID=51791434

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14787908T Active ES2768651T3 (es) 2013-04-25 2014-04-24 Composición farmacéutica sólida

Country Status (7)

Country Link
US (1) US9603804B2 (enExample)
EP (1) EP2990038B1 (enExample)
JP (2) JP5651812B1 (enExample)
CN (1) CN105338982B (enExample)
CA (1) CA2910112C (enExample)
ES (1) ES2768651T3 (enExample)
WO (1) WO2014174846A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014174847A1 (ja) * 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物
US10154993B2 (en) * 2014-10-23 2018-12-18 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
US20170246160A1 (en) * 2014-10-23 2017-08-31 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
JP6031217B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
US10206917B2 (en) 2015-06-02 2019-02-19 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
JP6031216B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
WO2016195021A1 (ja) * 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
WO2019191032A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
WO2021189018A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
EP4121050A4 (en) * 2020-03-20 2024-04-17 Clear Creek Bio, Inc. STABLE POLYMORPHOUS COMPOSITIONS OF BREQUINA SODIUM, METHODS OF USE AND PRODUCTION THEREOF

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
ZA87279B (en) 1986-01-17 1987-09-30 Chugai Pharmaceutical Co Ltd Method for production of stable nicorandil preparation
KR940000232B1 (ko) 1986-01-17 1994-01-12 쥬우가이세이야꾸 가부시끼가이샤 니코란딜 제제의 안정화 방법
JP2512302B2 (ja) 1986-03-19 1996-07-03 中外製薬株式会社 ニコランジル安定化製剤の製造方法
KR910700043A (ko) 1988-12-28 1991-03-13 우에하라 아끼라 타정시에 있어서 응력분산 방법
JP2682353B2 (ja) 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
TW284688B (enExample) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
JP2006111639A (ja) 1993-10-21 2006-04-27 Takeda Chem Ind Ltd 医薬用錠剤
JPH08175996A (ja) 1994-12-22 1996-07-09 Taiyo Yakuhin Kogyo Kk ニコランジル安定化固形製剤の製法
JP3119801B2 (ja) 1995-09-28 2000-12-25 武田薬品工業株式会社 ビタミン含有組成物の安定化方法
JPH10245335A (ja) 1997-02-28 1998-09-14 Dainippon Pharmaceut Co Ltd 圧力に不安定な薬物の打錠方法及びそれに用いられる湿潤顆粒
EP1066040B1 (en) 1998-03-03 2003-02-19 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
DE10048510A1 (de) 2000-09-29 2002-05-16 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
WO2002067943A1 (en) 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Oral pharmaceutical composition of cefpodoxime proxetil
US7219132B2 (en) 2001-03-30 2007-05-15 Space Systems/Loral Dynamic resource allocation architecture for differentiated services over broadband communication networks
US7153851B2 (en) * 2002-03-18 2006-12-26 Kyorin Pharmaceutical Co., Ltd. 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium
DK1459739T3 (da) 2003-03-19 2008-05-19 Jordanian Pharmaceutical Mfg Ikke-hydroskopiske farmaceutiske sammensætninger indeholdende ikke-hydratiserede quinolin-carboxylsyrer
PT1666477E (pt) 2003-09-10 2013-08-28 Kyorin Seiyaku Kk Derivado de 7-(4-substituído-3-ciclopropilaminometil-1- pirrolidinil) quinolonecarboxílico
CN1980670A (zh) 2004-07-02 2007-06-13 第一制药株式会社 含有喹诺酮的医药组合物
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
JPWO2006059716A1 (ja) 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
AR052559A1 (es) 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
ATE518526T1 (de) 2005-01-26 2011-08-15 Lek Pharmaceuticals Neue pharmazeutische zusammensetzung mit candesartan-cilexetil als lipophile kristalline substanz
JP2006298811A (ja) 2005-04-20 2006-11-02 Taiyo Yakuhin Kogyo Kk ゲル化抑制製剤の設計
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
WO2013145749A1 (ja) 2012-03-29 2013-10-03 杏林製薬株式会社 カプセル製剤
WO2013145750A1 (ja) * 2012-03-29 2013-10-03 杏林製薬株式会社 カプセル製剤
WO2014174847A1 (ja) * 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物

Also Published As

Publication number Publication date
CA2910112A1 (en) 2014-10-30
CA2910112C (en) 2021-02-16
US9603804B2 (en) 2017-03-28
JPWO2014174846A1 (ja) 2017-02-23
WO2014174846A1 (ja) 2014-10-30
US20160067185A1 (en) 2016-03-10
CN105338982A (zh) 2016-02-17
JP5651812B1 (ja) 2015-01-14
EP2990038A1 (en) 2016-03-02
EP2990038B1 (en) 2019-11-20
EP2990038A4 (en) 2016-11-16
JP6391436B2 (ja) 2018-09-19
JP2015078201A (ja) 2015-04-23
CN105338982B (zh) 2017-10-10

Similar Documents

Publication Publication Date Title
ES2768651T3 (es) Composición farmacéutica sólida
Scalera et al. A simple isolation method for basal-lateral plasma membranes from rat kidney cortex
US9329191B2 (en) Reaction-based fluorescent probe for selective detection of carbon monoxide using metal-mediated carbonylation
Yang et al. Diastereoselective synthesis of O symmetric heterometallic cubic cages
Chiocchio et al. Monoamines in the carotid body cells of the cat
CN104072390B (zh) 一种艾司西酞普兰化合物及其制备方法
CN110172028A (zh) 一种工业化生产妥洛特罗的方法
Saliba et al. Stimulating effect of both 4’‐O‐methylnorbelladine feeding and temporary immersion conditions on galanthamine and lycorine production by Leucojum aestivum L. bulblets
CN102786481A (zh) 新型厄洛替尼衍生物
CN100371709C (zh) 一种用液相色谱法分离测定匹伐他汀及其光学异构体的方法
Sundaresan et al. Alpha-and beta-adrenergic receptors in proximal tubules of rat kidney
Zea-Ponce et al. Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter
CN109689667A (zh) 多孔手性材料及其用途
Abreu et al. Characterization of the variation in the imidazole alkaloid profile of Pilocarpus microphyllus in different seasons and parts of the plant by electrospray ionization mass spectrometry fingerprinting and identification of novel alkaloids by tandem mass spectrometry
Németh et al. Synthesis and pKa determination of new enantiopure dimethyl‐substituted acridino‐crown ethers containing a carboxyl group: Useful candidates for enantiomeric recognition studies
Hannon et al. A cheap yet effective chiral stationary phase for chromatographic resolution of metallo-supramolecular helicates
Mills et al. 191. The configuration of the valencies of 4-covalent platinum: the optical resolution of meso-stilbenediamino iso butylenediaminoplatinous salts
CN107525877B (zh) 一种采用液相色谱法分离测定依匹哌唑及其杂质的方法
Dovrat et al. DOTP versus DOTA as Ligands for Lanthanide Cations: Novel Structurally Characterized CeIV and CeIII Cyclen‐Based Complexes and Clusters in Aqueous Solutions
Grinder-Hansen et al. Textiles and environment in the showcase containing Saint Canute the Holy († AD 1086): Radiocarbon dating and chemical interactions
AU720219B2 (en) New dosage form of hydroxocobalamin and its use in cyanide poisoning
Antoine Lanfranchi et al. Enantiomeric differentiation of atropine/hyoscyamine by 13C NMR spectroscopy and its application to Datura stramonium extract
US20190175643A1 (en) Production of water-soluble hydrolyzed clinoptilolite fragments
Wijeratne et al. Molecular recognition properties of tartrates and metal‐tartrates in solution and gas phase
Gregoliński et al. A New Synthetic Strategy Leading to Homochiral Macrocycles Derived from 2, 6‐Diformylpyridine and (1S, 2S)‐trans‐1, 2‐Diaminocyclopentane